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AbstrACt
Introduction Sedation is an essential part of paediatric 
critical care. Midazolam, often in combination with 
opioids, is the current gold standard drug. However, 
as it is a far-from-ideal agent, clonidine is increasingly 
being used in children. This drug is prescribed off-label 
for this indication, as many drugs in paediatrics are. 
Therefore, the CLOSED trial aims to provide data on the 
pharmacokinetics, safety and efficacy of clonidine for the 
sedation of mechanically ventilated patients in order to 
obtain a paediatric-use marketing authorisation.
Methods and analysis The CLOSED study is a 
multicentre, double-blind, randomised, active-controlled 
non-inferiority trial with a 1:1 randomisation between 
clonidine and midazolam. Both treatment groups are 
stratified according to age in three groups with the same 
size: <28 days (n=100), 28 days to <2 years (n=100) and 
2–18 years (n=100). The primary end point is defined 
as the occurrence of sedation failure within the study 
period. Secondary end points include a pharmacokinetic/
pharmacodynamic relationship, pharmacogenetics, 
occurrence of delirium and withdrawal syndrome, opioid 
consumption and neurodevelopment in the neonatal age 
group. Logistic regression will be used for the primary end 
point, appropriate statistics will be used for the secondary 
end points.
Ethics Written informed consent will be obtained from the 
parents/caregivers. Verbal or deferred consent will be used 
in the sites where national legislation allows. The study 
has institutional review board approval at recruiting sites. 
The results will be published in a peer-reviewed journal 
and shared with the worldwide medical community.
trial registration EudraCT: 2014-003582-24;  
Clinicaltrials. gov: NCT02509273; pre-results.
IntroduCtIon
Unlicensed and off-label drug use
In Europe, <30% of marketed drugs include 
results from paediatric clinical trials and 
other information on paediatric use in their 
documentation (Summary of Product Char-
acteristics (SPC) or Product Leaflet).1 This 
results in widespread off-label use in paediat-
rics, especially in the case of old drugs that 
have never received a paediatric authorisa-
tion. Off-label paediatric use (including all 
the uses not listed in the SPC2) in Europe 
accounts for 45%–60% of the total number 
of prescriptions, with rates of up to 90% in 
patients admitted to neonatal (NICU) or 
paediatric intensive care units (PICU).3
The entry into force of the Paediatric Regu-
lation in 20074 gave an important stimulus to 
support the development of medicines for 
children by introducing a specific measure 
to favour work on off-patent medicines, the 
so-called Paediatric Use Marketing Authori-
sation (PUMA). A PUMA application should 
strengths and limitations of this study
 ► The dosing scheme being used in this trial is based 
on detailed pharmacokinetic (PK)/pharmacodynamic 
modelling data.
 ► Pain and sedation are measured using a 
standardised assessment scheme—(COMFORT-B 
score)—across all participating units.
 ► Besides information on the efficacy and safety of 
clonidine in critically ill children, this trial will provide 
population-based PK information in this specific 
patient population.
 ► Age-specific formulations are being used in this 
trial, which can be marketed afterwards.
 ► A previous similar trial indicated challenging 
recruitment, this could be a potential threat to this 
trial.
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include the submission of paediatric data in accordance 
with an agreed Paediatric Investigation Plan (PIP).
According to article 40 of the Regulation, the European 
Commission (EC) reserved funds ‘to develop off-patent 
medicinal products with recognised therapeutic interest 
for children and included in a ‘Priority List’ adopted 
by the European Medicines Agency (EMA) through its 
Paediatric Committee (Seventh Framework Programme 
for Research HEALTH—(2007–2013) Programme area—
topic 4.2–1). Among 20 projects approved,5 the CLOSED 
project was granted with the aim to develop an age-appro-
priate formulation of clonidine for sedation in PICU, in 
line with the EMA ‘Revised Priority List for Studies into 
Off-Patent Paediatric Medicinal Products’ 2012.6 In order 
to specifically meet this therapeutic need, a comprehen-
sive development plan in the form of a PIP was submitted 
to the EMA Paediatric Committee (PDCO) in July 2012 
and approved in January 2013. In March 2015, a modifi-
cation of the PIP was proposed after the finalisation of the 
clinical study protocol. This modification was approved 
by the PDCO in August 2015.
Analgosedation in PICu
Approximately 2% of all paediatric patients admitted to 
hospital require treatment in PICU.7 Most PICU admis-
sions are unplanned emergencies, mainly in the context 
of congenital heart diseases (40%), respiratory diseases 
(20%), major trauma (15%) and neurological problems 
other than trauma (<10%).8
Often, mechanical ventilation is required for facil-
itating recovery after major surgery or for treating 
respiratory failure. In most of these cases, analgoseda-
tion using potent opioids and sedatives is mandatory 
to reduce metabolic rate and oxygen demand, assist 
mechanical ventilation, avoid inadvertent self-extuba-
tion and lower anxiety and distress.9 10 To this effect, a 
variety of agents are used in NICU and PICU, such as 
opioids, GABA-receptor agonists, N-methyl-d-aspartate 
receptor (NMDA)-receptor antagonists and α2-receptor 
agonists.11
opioids
The main opioids used in PICU and NICU are morphine, 
fentanyl and remifentanil. Opioids bind to the μ-receptor 
in the central nervous system (CNS), and provide anal-
gesia as well as sedation.
GAbA-receptor agonists
GABA receptors have an inhibitory effect on the CNS. 
Benzodiazepines agonise these receptors and therefore 
have sedative, anxiolytic and anticonvulsant properties. 
Disadvantages are paradoxal reactions (agitation and 
confusion) and tolerance and withdrawal after prolonged 
use.
Propofol is a unique agent with GABA-ergic proper-
ties as well as anti-NMDA and sodium channel blocking 
effects. Propofol is not suitable for long-term sedation, 
due to the perceived risk of propofol infusion syndrome, 
a metabolic derangement accompanied by severe 
metabolic acidosis, hyperkalaemia, hyperlipidaemia, 
rhabdomyolysis and organ failure, associated with an 
increased risk of mortality.12
Midazolam
Midazolam is the most widely used sedative agent in PICU. 
It is a short-acting benzodiazepine (Tmax of 5–10 min after 
intravenous injection) with a half-life of 1–3 hours (up to 
12 hours in neonates). Besides sedation and anxiolysis, 
midazolam also provides anterograde amnesia, thus mini-
mising children’s recall of unpleasant experiences after 
a PICU admission.13 Midazolam is mainly metabolised 
to the equipotent metabolite 1-OH-midazolam (1-OH-
MDZ), and then glucuronidated to the renally excreted 
1-OH-MDZ-glucuronide. Its main adverse effects include 
tolerance, dependence and withdrawal syndrome 
following discontinuation.
Clonidine
Clonidine agonises the α2-adrenergic receptor. The 
reduced sympathetic outflow14 in the CNS results in seda-
tion, anxiolysis and analgesia.15 16 Because of its analgesic 
properties, it has been used as an adjunct in surgical 
procedures as premedication or as a supplementary 
agent in regional anaesthesia.17 The reduction of sympa-
thetic outflow associated with clonidine may have specific 
benefits in critically ill children. A2 agonists can improve 
neurological outcome associated with ischaemic cerebral 
injury,18–20 the mechanism of action of which is unclear 
but may be due to suppression of extracellular glutamate 
and aspartate release during energy failure.21 Recent data 
have also demonstrated that preconditioning before the 
insult can both reduce infarct size and improve neurolog-
ical outcome after the insult.22 Surgery and critical illness 
are associated with a variety of stress responses, which can 
result in organ dysfunction:23 renal function deteriorates 
after both adult and paediatric cardiac surgery, and this 
effect is due in part to the increase in sympathetic outflow 
and the rise in circulating vasoconstrictors such as norepi-
nephrine, vasopressin and angiotensin.24 25 Clonidine 
has been demonstrated to suppress these responses and 
prevent the associated decline in renal function after 
adult cardiac surgery.26 In addition, clonidine has inde-
pendent local effects on tubular function which promote 
both diuresis and natriuresis.27 In terms of cardiovascular 
responses, reduction in stress responses by α2-agonists 
have been shown to reduce perioperative myocardial 
ischaemia in adults undergoing cardiac and non-car-
diac surgery.28 As the mechanism of action of clonidine 
is very different from the GABA-agonist midazolam, the 
hypothesis is postulated that it may be less associated with 
paediatric delirium and withdrawal syndrome. Moreover, 
clonidine is one of the agents used for the treatment of 
withdrawal syndrome.29
Previous clinical trials
Clonidine is commonly used off-label in paediatric 
anaesthesia and intensive care medicine. Its use is recom-
mended for the sedation of critically ill children in PICUs 
by the UK and German consensus guidelines12 30 and 
local hospital guidelines across Europe. Unfortunately, 
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despite this widespread use of clonidine, there are limited 
data on efficacy, dose requirement and safety when used 
for sedation on PICUs. A number of studies have been 
performed,31–35 however, to overcome this knowledge gap 
(see table 1 for a short overview).
study AIMs
For the purpose of sedation of intubated and mechani-
cally ventilated paediatric patients, this clinical study sets 
out to provide the data needed for a PUMA application 
for the use of clonidine in PICU patients:
 ► Data on efficacy and safety of clonidine compared 
with midazolam.
 ► Pharmacokinetic (PK) data on both clonidine and 
midazolam in critically ill children and adolescents, 
using a population-based approach.
Together with the development of age-adapted and 
weight-adapted formulations of clonidine, as part of this 
study, data on quality and stability of these new formula-
tions will also be generated.
MEthods/dEsIGn
Study design
The CLOSED study is a multicentre, double-blind, 
randomised, active-controlled non-inferiority trial with 
a 1:1 randomisation between clonidine and midazolam. 
Both treatment groups are stratified according to age in 
three groups with the same size: <28 days (n=100), 28 days 
to <2 years (n=100) and 2–18 years (n=100). The primary 
end point is defined as sedation failure within the study 
period.
Patient recruitment
Patients in five different European Union (EU) 
member states (Czech Republic, Germany, Italy, The 
Netherlands and Sweden) will be recruited. Patients 
(neonates ≥34 gestational weeks and children <18 years) 
eligible for inclusion in the trial, according to inclusion 
and exclusion criteria, will be screened for possible enrol-
ment (see table 2 for inclusion and exclusion criteria).
Surgery schedules will be screened on a daily basis for 
possible patients expected to be admitted to the intensive 
care unit (ICU). These patients and parents will be identi-
fied, approached, informed and enrolled prior to surgery 
by study responsible doctors and/or nurses. Patients 
eligible for inclusion transferred to the centres will be 
identified by the transport team. Patients admitted to the 
PICUs will continuously be screened by PICU medical 
staff to identify patients possible for enrolment. Parents 
of these eligible patients will be approached, informed 
and enrolled by study responsible doctors and/or nurses.
Children are often admitted to PICU/ NICU in an emer-
gency setting. Urgent action will most likely be required 
and the subject’s parent(s)/legal guardian(s) may not 
be immediately available to give consent. An example of 
this is when a critically ill baby is delivered by caesarean 
section, the mother may still be under anaesthesia while 
another parent/legal guardian of the child may not be 
present. Therefore, given the nature of the trial, espe-
cially considering that ICU patients are often admitted 
as a result of emergency, deferred consent/assent, as 
described in Article 35 of the new European Regulation 
on clinical trials (EU) No 536/2014 of the European 
Parliament and of the Council,36 is foreseen if allowed by 
local legislation, as described in section ‘Ethical consider-
ations’. This allows for the child to be enrolled in the trial 
before the parent(s)/legal guardian(s) are able to give 
Table 1 An overview of paediatric studies involving clonidine for sedation in the intensive care unit
Study Sample size and age Design Outcome
Ambrose et al.31 n=30, 0–10 years Three-step: intravenous Low-dose vs 
high-dose (variable dose together with 
midazolam), third group fixed dose
No adverse effects on 
haemodynamics, sufficient 
sedation in combination with 
midazolam
Arenas-Lopez et al.32 n=24, 0–5 years Prospective cohort study, oral clonidine as 
additive to morphine/lorazepam
Opioid-sparing and 
benzodiazepine-sparing, safe 
and effective
Wolf et al.33 n=129, 0–15 years Double-blind, randomised controlled trial 
of intravenous clonidine vs midazolam
No difference in effectivity, 
underpowered due to 
recruitment problems
Hünseler et al.34 n=219, 0–2 years Double-blind, randomised controlled trial 
of intravenous clonidine vs midazolam
Opioid-sparing and 
benzodiazepine-sparing in 
neonatal age group
Duffett et al.35 n=50, 0–18 years Double-blind, randomised controlled trial 
of oral clonidine vs placebo in addition to 
physician-driven sedation
No significant difference in 
effectivity, study with clonidine 
clinically feasible
*In summary, when used in addition to standard sedation management, clonidine has a benzodiazepine-sparing and opioid-sparing effect. 
Comparative studies showed equivalence, but were either underpowered33 or set up as a pilot trial.35
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consent, which is then sought once they are available. If, 
subsequently, deferred consent is withheld, the subject is 
removed from the study but a record will remain in the 
subject’s medical notes.
study treatments
First, it was necessary to define the dosing scheme so that 
appropriate drug concentrations could be used to main-
tain double blinding. A plasma clonidine concentration 
of around 2 μg/L gave adequate sedation combined with 
morphine infusion in ventilated PICU patients,32 and 2 
μg/L clonidine concentration also drops the Bispectral 
Index to 71 in adults.37 Clonidine has a long elimination 
half-life (16.9 hours in neonates, 11.4 hours in infants and 
7.4 hours in children38), so loading doses are proposed. 
It was therefore decided that loading and maintenance 
doses aimed at achieving steady-state concentrations 
of around 2 μg/L would be aimed for, and this scheme 
was designed by a PK/pharmacodynamic (PD) expert 
working group within the CLOSED consortium. Based 
on these doses, a similar dose scheme of midazolam was 
designed that would maintain double blinding.
The agreed dosing scheme consists of 15 min loading 
doses followed by a maintenance infusion rate. Increases 
or decreases, based on the evaluation of COMFORT-B 
and Nurses Interpretation of Sedation Score (NISS) 
score, in infusion rate are permitted, and preceding any 
increase, a loading dose over 15 min is specified. There 
are also compulsory lock-out times between each dose 
escalation or de-escalation to allow for new steady-state 
conditions to be approached. Participants will follow the 
dosing regimen, with 1 unit meaning 1 μg for clonidine, 
or 100 μg for midazolam:
 ► First bolus (T=0). Initial loading dose is 2 units/kg 
over 15 min and the following continuous infusion 
Table 2 Inclusion and exclusion criteria for the CLOSED trial
Inclusion criteria Exclusion criteria
Aged from birth (GA ≥34 weeks) to <17 years, 11 months 
and 1 week
Body weight <1200 g or GA <34 weeks
(Expected) admission to PICU Body weight ≤3 kg AND age ≥28 days
Body weight <10 kg AND age ≥2 years
Body weight >85 kg
(Expected) indication for mechanical ventilation (both 
invasive and non-invasive)
Clonidine within last 7 days prior to admission*
Sedation >72 hours prior to screening
Anticipated need for continuous sedation ≥24 hours Known hypersensitivity to clonidine, midazolam, morphine or 
propofol or any of their formulation ingredients and their rescue 
medication
Informed consent (or deferred consent if applicable) Administration of continuous muscle relaxants or other 
contraindicated drugs
Informed assent if applicable Postresuscitation within 24 hours or therapeutic whole-body 
hypothermia
CPAP or ECMO treatment
Severe organ insufficiencies:
 ►Renal failure according to pRIFLE63 or nRIFLE64 criteria
 ►Cardiac failure as defined by modified Ross class 3 or 4
 ►Arterial hypotension according to guidelines62
 ►Circulatory failure as defined by Goldstein criteria59†
Traumatic brain injury or other intracranial pathology including mental 
retardation and status epilepticus
Phaeochromocytoma, acute asthma or paralytic ileus‡
Severe bradycardia
Pregnancy
Known arterial hypertension in medical history
Previous participation in this trial at any time or previous participation 
in drug trial within last 3 weeks
Declined informed consent from parent(s)/legal guardian(s)
*This exclusion criteria has been removed in the second protocol amendment.
†These criteria have been modified in the second protocol amendment and allow for use of inotropes/vasopressor drugs.
‡The exclusion criteria acute asthma and paralytic ileus have been removed in the second protocol amendment.
CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation; GA, gestational age; nRIFLE, Neonatal Risk, 
Injury, Failure,  Loss of Function and End-stage renal disease; pRIFLE, Paediatric Risk, Injury, Failure,  Loss of Function and End-stage renal 
disease.
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1 unit/kg/hour will be administrated to all patients 
followed by 15 min lock-out period.
 ► Second bolus. If insufficient sedation after the fir st 
lock-out period, the second loading dose is 2 units/
kg over 15 min and the following continuous infusion 
1 unit/kg/hour will be administrated with a 15 min 
lock-out period.
 ► Third bolus. If insufficient sedation after the second 
lock-out period, the third loading dose is 2 units/kg 
over 15 min and the following continuous infusion 1.5 
units/kg/hour will be administered with a minimum 
of 105 min lock-out period.
 ► Fourth bolus. If insufficient sedation after the third 
lock-out period, the fourth loading dose is 2 units/
kg over 15 min and the following continuous infusion 
2 units/kg/hour will be administered followed by a 
105 min lock-out period.
 ► Fifth bolus. If insufficient sedation after the fourth 
lock-out period, the fourth loading dose is 2 units/
kg over 15 min and the following continuous infusion 
2 units/kg/hour will be administered with 24 hours 
lock-out period.
 ► Sixth to 11th bolus. If insufficient sedation after 
24 hours lock-out period, the 6th–11th loading dose of 
2 units/kg over 15 min and the following continuous 
infusion 2 units/kg/hour would be administered with 
at least 24 hours lock-out period between.
All doses are halved in patients younger than 1 month. 
Figure 1 shows the scenario of all loading doses of study 
drug administered for subjects.
Decreasing the maintenance dose will be possible 
in the case of oversedation (ie, COMFORT-B >22 OR 
COMFORT-B=11–22 and NISS=3).
Following steps will be taken to decrease the dose 
(doses are halved in neonates):
 ► 2 units/kg/hour will be decreased to 1.5 units/kg/
hour.
 ► 1.5 units/kg/hour will be decreased to 1 unit/kg/
hour.
 ► 1 unit/kg/hour will be decreased to 0.75 units/kg/
hour.
 ► 0.75 unit/kg/hour will be decreased to 0.5 units/kg/
hour.
If patients are still oversedated with the minimum 
dose, the Investigational Medicinal Product (IMP) 
administration will temporarily be stopped until 
patients need sedation again, and they will start back 
at T=0.
During the preparation of the trial, the consortium 
faced one unknown challenge. In V.1.0 of the protocol, 
dose reduction should be performed when a child is 
oversedated. After 30 min, a new sedation assessment 
should be performed and acted on the same. In an overse-
dated child, this could lead to a child being without IMP 
after 90 min (three dose reductions). This is certainly not 
a desirable situation, but not unthinkable as the half-life 
of both drugs are longer than 90 min. Therefore, a 6-hour 
observation period has been implemented. After a dose 
reduction, it is recommended to wait for 6 hours before 
the next dose reduction.
In this same amendment, another problem has been 
mitigated. Version 1.0 did not provide clear information 
about increasing the dose again after a prior decrease. 
In the amendment, it has been made clear that subjects 
having a decrease of maintenance infusion to <1 unit/
kg/hour will return to 1 unit/kg/hour, irrespective of 
the current infusion rate. If the decrease has been made 
while increases before have led to a maintenance infusion 
rate of ≥1 unit/kg/hour, reincrease will be following the 
precedent step (eg, if a decrease has taken place from 1.5 
to 1 unit/kg/hour, reincreasing will return the rate back 
to 1.5 unit/kg/hour).
Pharmaceutical development
To overcome the potential for administration errors associ-
ated with commercially available clonidine ampoules, three 
different strengths of clonidine HCl—low (250 μg/50 mL), 
medium (500 μg/50 mL) and high (2500 μg/50 mL)—have 
been developed. Based on the dosing regimen described 
above, the concentrations of the low, medium and high 
strengths of midazolam (25 mg/50 mL, 50 mg/50 mL and 
250 mg/50 mL) were 100-fold higher than for clonidine 
HCl. For study blinding purposes and to avoid dosing 
errors, a simple three-colour scheme based on strength will 
be used.
To avoid the administration of preservatives, all formu-
lations will be stored in single-use glass phials, with any 
contents remaining after 24 hours to be discarded. A 
50 mL volume has been selected to limit the number of 
children requiring more than one phial in 24 hours (only 
subjects weighing over 46 kg and receiving the maximum 
Figure 1 Minimum time line of infusion rate increases for all loading doses of IMP administered for subjects (half doses in 
neonates).
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dose in 24 hours will require two phials in a 24-hour 
period).
Efficacy end points
Level of sedation was evaluated using the COMFORT-B 
score (ranging from 6 to 30), which is a validated scoring 
system commonly used in PICU.39 Level of sedation was 
also evaluated by NISS when the COMFORT-B score fell 
between ≥11 and ≤22. NISS is the nurse’s expert opinion 
of the level of sedation (1: insufficient sedation; 2: 
adequate sedation; 3: oversedation). A subject is consid-
ered to be undersedated in cases of COMFORT-B score 
of >22; or COMFORT- B score of 11–22 in combination 
with NISS of 1.
In addition to COMFORT-B score (and NISS where 
appropriate), pain was assessed using the Numerical 
Rating Scale (NRS) at the same time intervals. The 
11-point NRS is a global pain rating scale with which 
the nurse rates pain intensity by number (0=no pain 
and 10=worst imaginable pain).40 In this study, to 
simplify matters, the NRS score was addressed first, 
so, if the pain score was ≥4, morphine treatment was 
escalated while sedation treatment remained the same, 
regardless of the COMFORT-B score. This means that 
any pain score took precedence over the sedation 
score.
Primary objective
To assess the non-inferiority of the sedative properties of 
continuous intravenous clonidine compared with contin-
uous intravenous midazolam in mechanically ventilated 
children and adolescents (0–18 years) admitted to a PICU.
Primary end point
The primary end point is defined as sedation failure 
within the study treatment period (a maximum of 7 days).
Sedation failure is defined as:
When a subject’s assessment results are:
NRS score <4 and COMFORT B score >22 OR
NRS score <4 and COMFORT B score ≥11 and ≤22 AND 
NISS score 1 at a point during the study where no further 
increase in IMP dose are permitted as described in the 
dose-escalation scheme.
In summary, there are two possible outcomes (success 
or failure) of the primary end point.
secondary objectives
To evaluate the safety and tolerability (including with-
drawal effects) of clonidine compared with midazolam 
in ventilated children and adolescents admitted to PICU.
To determine clonidine dose-dependent effects on 
sedation.
To establish the PK/PD relationship of clonidine for 
sedation in PICU.
To compare the cumulative total morphine consump-
tion/kg between the two arms in the first 48 hours of IMP 
administration.
secondary end points
Primary PK parameters estimated will be clearance (CL), 
volume of distribution (VD) and intercompartmental 
clearance (Q). PK measurements will be made using 
sparse opportunistic sampling.
PK/PD modelling will seek to elucidate the relation-
ship between IMP PKs and sedation as measured by 
COMFORT-B score.
The PK/PD covariate model will include demographics 
(eg, age, weight), clinical characteristics (eg, reason for 
admission) and pharmacogenomics (see the 'Pharmacog-
enomic end points' section).
safety and tolerability assessments
Safety and tolerability assessments include:
 ► Extent of withdrawal effects using the Sophia 
Observation withdrawal Symptoms-Paediatric 
Delirium (SOS-PD) scale measured three times a day 
in subjects who receive sedatives and/or opioids for 
5 days or more and after cessation of treatment in 
all subjects for at least 24 hours after treatment. The 
extent of delirium measured by the SOS-PD scale.41
 ► Rebound hypertension monitored for at least 72 hours 
postcessation of treatment.
 ► Percentage of respiratory depression per group.
 ► Adverse event reporting of symptoms indicative 
of post-ICU stress (eg, nightmares, confusion, 
hallucinations).
 ► Neurodevelopment of subjects recruited in lower 
age group (from birth to 27 days) at 12 months after 
cessation of IMP, as measured using the Bayley II 
score.42
Effect size justification
The primary objective of this study is to evaluate the 
efficacy of clonidine compared with midazolam in the 
sedation of ventilated children and adolescents admitted 
to PICU, with a view to demonstrate non-inferiority of 
clonidine.
Every patient enrolled will be in need of sedation, thus 
a placebo cannot be considered. Intravenous midaz-
olam is the standard treatment for long-term sedation 
in children. It is licensed in this population, regarded as 
standard of care and recommended by treatment guide-
lines.12 30
Based on clinical experience and the limited data avail-
able regarding the use of clonidine as a sedative agent 
in PICU, it is assumed that the sedation success rate for 
clonidine is higher than for midazolam. The estimated 
difference in success rate between the two drugs was 
assumed to be 5%.
The primary end point is the success or failure of the 
subject’s sedation treatment. Failure is defined as inade-
quate sedation with no further dose increases allowed in 
the dose titration scheme. This will be assessed by a nurse 
or physician using the COMFORT-B sedation assessment 
and, if appropriate, NISS. These assessment scales are 
open to a degree of subjectivity and it is therefore consid-
ered essential to have a double-blind study design to 
minimise bias due to knowledge of treatment group by 
the assessor.
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In order to define the effect size, the expected success 
rate for midazolam was needed. The target concentration 
for midazolam was taken from the paper by de Wildt et al43 
showing around 311 μg/L is required for sedation.43 The 
maximum midazolam dose of 200 (100–200) μg/kg bolus 
followed by 200 (50–200) μg/kg/hour for all age groups 
(including neonates) is recommended by Dutch clinical 
consensus guideline.44 According to the proposed dosing 
schedule, the exposure of midazolam is similar to the 
Dutch recommended dosing regimen from the simula-
tion (figure 2).
Furthermore, after the fifth bolus according to the 
proposed dose scheme, the proportion of average 
midazolam plasma concentration above the target value 
(0.311 mg/L) is 74% and from the Dutch dose scheme is 
72%. Thus, we assumed that the sedation success rate in 
the midazolam arm given our dosing scheme would be 
75%, and in the clonidine group this would be 80%.
sample size calculation
Given this assumed effect size of a 75% success rate for 
midazolam, a sample size of 258 (129 per treatment arm) 
provides at least 80% power to show non-inferiority of 
clonidine compared with midazolam. The sample size 
calculation is based on a logistic regression for the primary 
efficacy end point of sedation success, with adjustment for 
study arm, age category and baseline COMFORT-B score. 
Non-inferiority of clonidine requires that the lower limit 
of the one-sided 97.5% CI for the OR of sedation success 
using clonidine (vs midazolam) is at least 0.583, which is 
equivalent to a 10% non-inferiority margin in case of a 
sedation success rate of 80%. The required sample size 
was calculated using simulation.
It is assumed that the total drop-out rate will be <13% 
and hence 300 subjects will be recruited, 150 in each arm 
and 100 in each age subgroup. The sample size of 300 
subjects also provides at least 70% power to prove non-in-
feriority with respect to sedation success rate for each 
age subgroup (>90 subjects per age subgroup). Since the 
sample size for the age subgroup analyses is limited, a 
15% non-inferiority margin at a one-sided alpha level of 
0.025 is used, with an assumed sedation success rate of 
80% in the midazolam group and 85% in the clonidine 
group. Subgroup analyses will be performed using a CI 
for the Mantel-Haenszel risk difference, with stratification 
by centre.
statistical analysis
Analysis populations
The safety evaluation set (SES) is the subset of all subjects 
who were randomised into the trial and exposed to study 
medication (also referred to as the intention-to-treat (or 
ITT) population). Safety analyses will be performed in 
the SES.
The full analysis set (FAS) is the subset of subjects in the 
SES for whom the primary efficacy variable is available. 
Data analysis for the efficacy end points will be performed 
in the FAS.
The per protocol set (PPS) is the subset of subjects 
in the FAS without major protocol deviations. Major 
protocol deviations will be defined during the Blinded 
Data Review Meeting.
The PK/PD analysis set (PKS) is the subset of subjects 
in the SES with evaluable PK samples defined as drug 
concentration measurements.
Primary efficacy analysis
Logistic regression of the primary end point, sedation 
failure, with treatment group, baseline sedation assess-
ment (ie, the baseline COMFORT-B score), centre and 
age group as covariates, at a one-sided significance level 
of alpha=2.5% will be used. The statistical hypotheses are 
the following:
H0: OR≤ δOR and H1: OR>δOR,
OR=pC*(1−pM)/((1−pC)*pM), where pC and pM  are 
probabilities of sedation success in the clonidine group 
and midazolam group, respectively; δOR is the non-inferi-
ority margin which is predefined as 0.583.
H0 will be rejected if the lower bound of the one-sided 
97.5% Wald CI for the OR of sedation success propor-
tion will be  >0.583. The primary analysis will be based 
on the ITT principle. The primary end point will be eval-
uated for FAS. An equivalent analysis for the PPS will be 
performed as a sensitive analysis. No interim analyses are 
planned for the primary end point.
Figure 2 The proportion of average midazolam plasma concentration above the target value (0.311 mg/L) after the time of 5th 
bolus according to the proposed dose scheme(left) and the maximum Dutch recommended dosing regimen(right).
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secondary efficacy analyses
All secondary efficacy analyses will be conducted on FAS. 
Secondary efficacy end points will be analysed in detail as 
follows:
 ► The proportion of subjects with sedation success 
between treatments within each age group will be 
based on the Mantel-Haenszel risk difference, with 
stratification by centre.45 A 15% non-inferiority 
margin at a one-sided alpha level of 0.025 will be used.
 ► The aggregate intervals (ie, the total time) (based on 
the planned assessment points) with COMFORT-B 
score >22 or <11 during treatment period between 
treatment groups were analysed using the Mann-
Whitney U test.
 ► The proportion of subjects with COMFORT-B 
score ≤11 between treatment groups and within each 
age group will be analysed using the χ2 test or Fisher’s 
exact test.
 ► The morphine consumption in units of μg/kg/day 
during the first 24 hours of IMP administration and for 
the remaining study period between treatment groups 
will be analysed using linear regression analysis, with 
adjustment for centre and age group. An appropriate 
transformation of morphine consumption may be 
used to ensure normality of the residuals in the linear 
regression model.
An age subgroup analysis will be performed for each age 
group, using centre as a stratification variable.
PK/Pd analyses
The primary objective of PK/PD analyses in this trial is to 
evaluate the pattern and extent of covariates affecting the 
PK/PD profiles of clonidine and to provide the informa-
tion of optimal dose for patients based on their particular 
age and other related covariates for future clinical prac-
tice. Three PK/PD interim analyses will be undertaken, 
whereby samples will be shipped and assayed for drug 
concentrations in order to ensure the systems for sample 
transport and analysis, along with data linkage to the elec-
tronic Case Record Form (eCRF) are fully operational, 
and to allow preliminary PK/PD model development. 
PK/PD interim analyses will be conducted after 15, 100 
and 200 subjects will complete the study.
PK/PD data will be modelled using the Fortran-based 
non-linear mixed effects software NONMEM. Typical 
PK dispositional compartmental models will be  tested, 
along with investigation of linear and non-linear elimi-
nation. Multivariate covariate analysis will be undertaken 
to investigate the impact of subject factors on PK model 
parameters. In particular, we will focus on the effect of 
body size with allometric models, and age (both post-
menstrual and postnatal) possibly using literature prior 
models in order to delineate the effect of size and age 
from other factors. We will also look at the impact of 
drug metabolising enzyme genotype on interindividual 
variability. The link between PK and PD (COMFORT-B 
score) will be investigated by sequential and simultaneous 
modelling, possibly including an effect compartment. 
The Item Response Theory (IRT) will also be consid-
ered for PK/PD modelling, whereby effect is considered 
an unobserved normally distributed latent variable, and 
each item score of COMFORT-B is allowed to contribute 
to this through link functions.46 Since subjects will receive 
other sedative agents for procedures, the concentrations 
of which may not be measured, a PK/PD approach will 
be taken to model sedation requirements in this period.
Mixed effects models will be fitted with maximum like-
lihood and addition of a single fixed effect will be guided 
by improvement of fit using the likelihood ratio test. 
Model evaluation will consist of goodness-of-fit (residual 
plots) and simulation-based diagnostics (visual predictive 
check), and parameter precision and robustness will be 
investigated with non-parametric bootstrapping.
safety analyses
All safety analyses will be performed on the SES. Analyses 
will include the following end points:
 ► Adverse Event (AE)s, Serious Adverse Event (SAE)
s and Suspected Unexpected Serious Adverse 
Reaction (SUSAR)s.
 ► Deaths.
 ► Clinical laboratory evaluations and vital signs. 
Descriptive summaries of laboratory values (including 
clinical chemistry, haematology, coagulation and 
urinalysis variables) and changes from baseline 
throughout the study will be generated. Shift tables 
will also be used for comparing changes from 
baseline and the proportion of subjects experiencing 
abnormalities between treatment groups.
 ► The SOS scores will be descriptively summarised and 
analysed with a linear mixed model (with between-
arm differences at baseline constrained to be 0).
 ► Neurodevelopment will be evaluated using the Bayley 
Scales of Infant and Toddler Development. The 
scale will be descriptively summarised and compared 
between treatment groups using linear regression 
analysis, with adjustment for centre and age group.
Quantitative variables will be by the number of subjects 
analysed (N), mean, median, minimum and maximum. 
Categorical variables will be analysed by frequencies and 
percentages for each category.
rAndoMIsAtIon And KIt AssIGnMEnt
Randomisation is stratified by both age subset and clinical 
site. Each stratum consists of 99 prerandomised numbers 
(randomisation numbers), assigned to either clonidine 
or midazolam. These randomisation lists were prepared 
by a statistician not otherwise involved in the study, with 
the use of blocked randomisation consisting of small 
variable block sizes, in order to maintain blinding and 
conceal allocation.
At each clinical site, the kits marked with the random 
numbers for each age subset will be assigned to subjects 
in the order they are enrolled into the study. Each subject 
kit will contain two IMP boxes of seven phials, in order 
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to supply the subject with enough medication for the 
maximum 7-day study period. The contents of each 
subject kit is outlined in table 3.
Emergency unblinding will be possible as for each 
randomised subject kit, two complete sets of sealed 
emergency envelopes have been prepared (one set 
for safekeeping by the investigator, the other will be 
delivered to the group responsible for overseeing phar-
macovigilance of the study). Unblinding of the treatment 
allocation for a subject will be performed in an emer-
gency that, in the opinion of the investigator, is warranted 
for a given subject for safety reasons.
PK/Pd End PoInts
PK/PD analyses will be carried out as a secondary 
end point to give further information on the dose-con-
centration-effect relationship primarily of clonidine, and 
also of midazolam. The PK/PD model will be used to eval-
uate the dose scheme used in the study, and if necessary 
recommend an updated dose scheme for clinical use. 
PK/PD data will be modelled using non-linear mixed 
effects modelling. The impact of drug metabolising 
enzyme genotype on interindividual PK/PD variability 
will be considered alongside other demographics in the 
multivariable covariate analysis. The link between PK and 
PD (COMFORT-B score) will be investigated by sequen-
tial and simultaneous modelling, possibly including an 
effect compartment. IRT will be explored for PK/PD 
modelling, whereby effect is considered an unobserved 
normally distributed latent variable, and each item score 
of COMFORT-B is allowed to contribute to this through 
link functions.46
Mixed effects models will be fitted with maximum 
likelihood and addition of a single fixed effect will be 
guided by improvement of fit using the likelihood ratio 
test (change in objective function of 3.84 is significant at 
p=0.05 level for 1 df by the χ2  distribution). Model eval-
uation will consist of goodness-of-fit (residual plots) and 
simulation-based diagnostics (visual predictive check), 
and parameter precision and robustness will be investi-
gated with non-parametric bootstrapping.
PhArMACoGEnoMIC End PoInts
Patients treated with sedatives and analgesics may respond 
very differently to the same dosage of medication. Several 
gene polymorphisms have been discovered to influence 
the PK and PD of clonidine, midazolam and morphine. 
PK data collected in this study can be interpreted more 
completely if data on pharmacogenomics are available.
Moreover, to study candidate polymorphisms gives 
further insight into the response of critically ill children 
to clonidine, midazolam and morphine. Most candidate 
genes have been established in adult subjects, this study is 
an opportunity to study the effects in children. The candi-
date genes which will be genotyped are shown in table 4.
EthICAl ConsIdErAtIons
Ad hoc considerations and measures have been set up to 
ensure safe and ethical conduct of this multinational trial, 
including a population requiring special protection such 
as children. In order to guarantee the respect of ethical 
rules regardless of the country in which the trial is carried 
out, an ethical standard based on the EU ethical and legal 
framework has been agreed among centres. All submis-
sions are based on the current European ethical and legal 
framework and on the international ethical principles 
and guidelines.
Based on the Council of Europe Convention on Human 
Rights and Biomedicine47 and EU Ethical Recommenda-
tions 2008,48 research involving vulnerable populations 
is allowed if the results of the research are expected 
to provide real and direct benefit to the health of the 
patient, or some benefit for the population represented 
by the patient, and the trial will pose only minimal risk 
and burden to the individual concerned. The risk-ben-
efit assessment has been carefully addressed considering 
IMP-related risks (including pharmacological properties 
and proposed dosing regimen of the IMP, information 
on use in target population, IMP development, IMP 
management) and expected benefits, the trial design 
(including study population inclusion and exclusion 
criteria), study-related procedures, qualification of the 
Table 3 Composition of the subject kit for each age group
Age subset Age group Formulation strength Subject bodyweight Number of boxes
1 <28 days Low
Medium
≤3 kg
>3 to <10 kg
1
1
2 28 days to <2 years Medium
High
>3 to <10 kg
≥10 kg to <47 kg
1
1
3 ≥2 years to <18 years High ≥10 kg to 85 kg 2 (in case ≥47 kg)
Table 4 Candidate genes for linking pharmacogenomics to pharmacokinetic and pharmacodynamics end points
Midazolam Clonidine Morphine
CYP3A4, CYP3A5, POR, ABCB1, GABA, 
MDR1, MRP1, MRP2, MRP4, BRCP
ADRA2A, CYP2D6 COMT, OPRM1, OCT1, UGT2B7, ABCC3, MC1R, 
IL-1Ra, IL-1β, ARRB2, STAT6
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study team and host sites, rights of patients (including 
informed consent and assent procedures and data protec-
tion and confidentiality). Minor increase over minimal 
risk is anticipated for the CLOSED trial, as the study deals 
with a novel treatment modality in vulnerable paediatric 
patients and carries minor risk based on the available 
information about the study drug as well as randomised 
controlled trial (RCT)-related procedures. Important 
benefits for PICU population as a group are anticipated, 
since the study will provide clinically relevant and directly 
applicable results, expected to influence future standard 
of care.
The informed consent and assent process in this trial is 
in line with the applicable relevant regulatory documents, 
including Good Clinical Practice (GCP) guideline,49 
Directive 2001/20/EC,50 the EC Detailed Guidance 
2006,51 Directive 95/46/EC,52 the International Ethical 
Guidelines for Biomedical Research Involving Human 
Subjects CIOMS-WHO (2002),53 the Additional Protocol 
to the Oviedo Convention (2005),54 ICH Topic E11 and 
the EC 2008 Paediatric Recommendations. Accordingly, 
clear and appropriate information sheets and informed 
consent forms for parents/legal representatives, and 
patient information sheets and assent forms are prepared 
for patients and customised according to the local 
requirements.
Given the nature of the trial, especially considering 
that ICU patients are often admitted as a result of emer-
gency, deferred consent/assent, as described in Article 
35 of the new European Regulation on clinical trials 
(EU) No 536/2014 of the European Parliament and of 
the Council,36 is foreseen if allowed by local legislation. 
Informed consent of the legal representative and, if 
feasible, the patient’s assent will be sought for as soon as 
possible. If informed consent is not obtained, the possi-
bility of withdrawing all collected data from the trial 
will be explained and appropriate measures, based on 
patient’s decision will be taken. A record will remain in 
the subject’s medical notes. In the Netherlands, deferred 
consent is permitted under national legislation (‘Wet 
medisch-wetenschappelijk onderzoek met mensen’, Para-
graph 2 Article 6.4).
As the protocol includes pharmacogenetic tests, 
informed consent and assent to perform genetic tests 
will be obtained separately, in line with the most rele-
vant provisions in the field (International Declaration on 
Human Genetic Data, UNESCO, 2003;55 Ethical Guide-
lines CIOMS-WHO, 2002). Accordingly, the participants 
will have the possibility to join the trial without partici-
pating in the pharmacogenetic part.
Finally, involvement of appropriate external expertise in 
the form of Data Safety Monitoring Board (DSMB), Inde-
pendent Scientific Advisory Board (ISAB) and Patient 
Advisory Board (PAB) is foreseen. In details, the DSMB 
will review the study’s safety data and assess subject safety 
data throughout the study; the ISAB will input in the final 
protocols, monitor the progress of the project and ensure 
the ongoing scientific and ethical integrity of the clinical 
trial; the PAB will advise the Sponsor to ensure that the 
subjects’ rights and subjects’ protection will outweigh any 
commercial considerations and conflicts of interest that 
may appear in relation to the project.
In accordance with GCP, as implemented at national 
level, the study protocol and related documents have 
been approved by the competent ethics committees in 
Rotterdam, the Netherlands, and in Erlangen, Germany. 
Submission is currently being prepared for the three 
other centres (Stockholm, Prague and Rome).
dIssEMInAtIon
The results will be published in a peer-reviewed journal 
and shared with the worldwide medical community.
dIsCussIon
Study design
Sedation management in PICU mainly consists of the use 
of intravenous midazolam by continuous infusion. Midaz-
olam has several advantages, but is by far not the ideal 
agent for longer-term sedation. Other agents have made 
their off-label entry into PICU, mainly based on adult 
practice. One of these agents is clonidine, which could 
have some specific advantages over midazolam. It is being 
used increasingly, but is still off-label. This study design 
allows for data collection on safety, efficacy, PK, pharma-
cogenomics and to a lesser extent neurological outcome. 
This multimodal approach generates data that is very 
useful for licensing clonidine for sedation in children. 
Moreover, application of different formulation strengths, 
allows for easier paediatric clinical implementation as the 
current available formulation (Catapresan) has only been 
developed for adults.
study limitations
Despite the careful design of this trial, some limitations 
exist. First, we have chosen a non-inferiority design 
for this trial because, based on clinical experience and 
limited available data, we estimate the difference in 
sedation success rate will be very low. This would mean 
that showing superiority of clonidine requires a large 
sample size and thus compromising feasibility. This 
design, however, means that we cannot demonstrate 
possible superiority of clonidine. However, if equal effi-
cacy is shown under safe circumstances, clonidine can be 
licensed for sedation in PICU.
Second, the recruitment window has been set on 
72 hours. This could lead to confounding as having a 
large time window could increase the risk of tolerance 
and withdrawal symptoms. A smaller recruitment window 
may reduce these risks but parents need some time to 
consider participation and not every study site has 24/7 
research nurse availability.
Third, this trial has an extensive list of exclusion 
criteria. This could compromise the external validity 
of the results and could complicate implementation of 
the results in new guidelines. This is a known limitation 
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of almost any controlled trial.56 However, these exclu-
sion criteria are based on expected elements affecting 
both primary outcome and patient safety. Our primary 
end point is based on a validated behavioural scale. There-
fore, any disease status that can cause many fluctuations 
in behaviour (such as neurological injury) needed to be 
excluded from this trial for the results to be valid. The 
same holds for safety end points such as cardiovascular 
stability. The decision to allow for inotropes/vasopressors 
in the second amendment is a big step towards generalis-
ability of the results.
role of researcher-driven studies, seventh Framework 
Programme-funded projects
CLOSED is one of the 20 projects approved in the frame-
work of the Seventh Framework Programme for Research 
that should specifically meet both criteria for scientific 
excellence and regulatory standards for high-quality 
paediatric research, as prescribed by the Paediatric Regu-
lation, in order to put paediatric drugs on the market. A 
very recent publication demonstrated that these projects 
face the need for overcoming the existing methodological 
and ethical difficulties affecting research in the paediatric 
population.5
In fact, paediatric clinical trials are often multinational 
and researchers need to know and apply rules from the 
regulatory, legal and ethical frameworks, acting both as 
investigators and as sponsor and/or other concerned 
parties. This is not simple considering the lack of harmon-
isation of clinical trial procedures among countries 
(http://www. ncbi. nlm. nih. gov/ pubmed/ 26037896) and 
makes it necessary to prepare, agree and apply guidelines 
based on the EU rules.
Challenge to perform a trial compliant with GCP and other 
regulations
Clinical trials must follow the same rules, notwithstanding 
if sponsored by industry or non-profit organisations, from 
GCP to the new clinical trials regulation49 to recommen-
dations and guidelines.
Accordingly, the new regulation49 recognises that a large 
proportion of clinical trials are conducted by non-com-
mercial sponsors, frequently supported by public funds 
or charities and that these trials should be encouraged.
However, this means a heavy work from researchers and 
a deep knowledge of both EU and national rules. This issue 
is aimed to be overcome by the international public-pri-
vate cooperation between different stakeholders foreseen 
by EU-funded projects (researchers, clinicians, regulatory 
and ethical experts, clinical research associates). On the 
other hand, it seems that the paediatric Consortia gener-
ated by the FP7 paediatric projects are conducting these 
studies and trials using a limited amount of money in 
comparison with the recognised cost of paediatric trials 
in an approved PIP which is estimated to be three to four 
times higher.5
Challenges of maintaining double-blinding
Clonidine and midazolam have different half-lives: 
1–3 hours for midazolam (up to 12 hours in neonates) 
and 9–17 hours for clonidine, thus maintaining double-
blinding is challenging. PK/PD simulations have played 
a major role in the strategy to overcome this challenge. 
It has led to the implementation of a loading dose, which 
is in line with the current clinical recommendations for 
midazolam.44 Target plasma levels have been achieved 
based on the literature.32 43 It should be noted, however, 
that the PK/PD relationship is assumed, but not formally 
studied. This study will contribute to the determination 
of a PK/PD relationship.
risk to patients
Both clonidine and midazolam are frequently used seda-
tives in PICU. However, a careful assessment of possible 
study-related risks has been performed. In general, side 
effects of IMP are the major cause of study-related risk. 
As midazolam is the gold standard treatment, the side 
effects do not contribute to an increased risk in this 
study. For clonidine, bradycardia and hypotension are 
the most clinically relevant side effects and are likely to 
occur most often during the loading doses and the early 
starting phase.33 Therefore, a loading dose will be given 
as a 15 min infusion instead of a direct bolus. Moreover, 
the setting where patients are being monitored consists of 
five well-equipped and experienced PICUs. Treatment of 
hypotension and/or bradycardia is common practice in 
the study population and should therefore not increase 
the risk to subjects dramatically.
Rebound hypertension could also be a side effect after 
sudden discontinuation of clonidine. In a comparable 
trial,31 this was observed once in 64 patients and resolved 
quickly without any intervention. Monitoring of blood 
pressure up to 72 hours after IMP cessation has been 
included in the study protocol with the recommendation 
to treat hypertension according to local common prac-
tice.
Blood sampling is a possible risk to small children 
participating in drug research.57 In this study, the amount 
of sampled blood will not exceed the 3% of patient’s 
plasma volume, which is a general limit of study-related 
blood sampling.
In general, as most elements of this study are similar to 
current clinical practice, the study-related risk to patients 
is deemed low.
Pharmacogenetics
This study incorporates a pharmacogenetics assessment 
of recruited patients. Both PK and PD may be influenced 
by gene polymorphisms. The current proposed pharma-
cogenetics assessment has been based on the literature 
available, but a degree of flexibility has been built in 
when more information on these genes or medications 
will come available.
In accordance with the appropriate regula-
tions,51 53 55 separate consent and assent will be obtained 
from participants. This strategy enables the possibility of 
participating in the CLOSED trial without the genetic 
assessment.
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Anticipated difficulties
A comparable RCT, the Safety profiLe, Efficacy and Equiv-
alence in Paediatric intensive care Sedation (SLEEPS) 
study, has been previously undertaken in the UK.33 One 
of the major challenges faced by the investigators was 
the recruitment. The sample size had been calculated 
on 1000 subjects. Unfortunately, only 129 subjects were 
randomised. Contributing factors to this impaired recruit-
ment have been identified by the investigators, including:
 ► Conflict with other studies
 ► Earlier extubation in elective cardiac surgery patients
 ► Parental issues and timing of consent
 ► Clinicians’ issues
 ► Research nurse time
 ► Delay in study start
 ► Compliance with the protocol.
It is likely that in the participating centres with excellent 
research facilities, multiple trials are being performed at 
the same time. Children are not allowed to participate in 
multiple intervention studies, so we recommend to have 
a thorough look at the inclusion and exclusion criteria of 
studies and set up clear agreements about patient alloca-
tion.
Early extubation in cardiac surgery patients is now 
common practice, and estimations of recruitment rates 
have excluded these patients. However, it is likely that 
ventilation strategies will change over the coming years. 
We have recognised the increasing use of non-invasive 
ventilation such as Non-Invasive Positive Pressure Ventila-
tion (NIPPV). As these patients may still need continuous 
sedation, we will include these in the study. In general, 
patients on continuous positive airway pressure (CPAP) 
do not need additional sedation, thus these will be 
excluded.
Parental issues are to be expected in any clinical trial in 
the PICU. Parents having their child admitted to an ICU 
are under high stress and may therefore be reluctant 
to participate. In the calculations of estimated recruit-
ment, a high refusal rate (approximately 40%–50%) 
should be taken into account, based earlier experience 
with other trials. Also, a parent organisation is involved 
in the trial and they will provide information to parents 
from their perspective. We anticipated to include 300 
patients within 18–24 months in total. In The Nether-
lands, deferred consent is used in emergency care trials. 
The Ethical Committee of the Erasmus Medical Centre, 
Rotterdam, has approved the use of deferred consent in 
this trial so this could be applied in the largest recruit-
ment centre.
When faced with a critically ill child, doctors and nurses 
may tend towards conservatism. At the beginning of the 
SLEEPS trial, the involved professionals could have been 
afraid of the cardiovascular side effects of clonidine espe-
cially in unstable patients. Their study has shown that 
its use is relatively safe in critically ill children, as well as 
other literature.34 58 Moreover, in the CLOSED consor-
tium recruitment centres, a lot of clinical experience with 
clonidine has been built so caregivers may be less hesitant 
to support this clinical trial.
Research nurse time is always an issue, especially in the 
24/7 business of an ICU. In the larger centres, dedicated 
researchers/nurses have been identified and trained 
adequately to perform this trial. In the smaller centres, 
Principle Investigators (PI)s may be able to coordinate 
the lower amounts of participants.
During the first months of patient recruitment in two 
centres, no patients could be included. In the majority 
of cases, exclusion criteria made the screened patients 
ineligible. No consent was given in the very few eligible 
patients. Therefore, a revision of the exclusion criteria 
has been made.
The major exclusion criteria on which patients failed 
screening are:
 ► Anticipated need for sedation <24 hours. It has been 
considered to change this duration. It has been 
decided however to keep this minimum as the 
therapeutic aim of the study is long-term sedation.
 ► No sedation despite ventilation. To our surprise, many 
newborn patients on the ventilator would not need 
any sedation, or were comfortable on low-dose 
opioids. This could not be mitigated.
 ► Circulatory insufficiency. The Goldstein criteria59 
have been used for the definition of this exclusion 
criterion. However, many patients received inotropic 
or vasopressor agents as supportive therapy in both 
recruiting centres. We have therefore modified 
these criteria and removed the use of inotropes/
vasopressors in the second protocol amendment.
 ► Neurological pathology. It has been suggested to include 
patients with minor head trauma, but as the clinical 
picture may change very rapidly, we have decided not 
to include these patients into the trial.
 ► Use of clonidine in the last 7 days. As clonidine has a 
long half-life, patients would be excluded if they 
have received clonidine for any indication in the 
previous 7 days. However, for midazolam, there was 
no similar exclusion criterion; instead, patients would 
undergo an extra PK blood sample before start of the 
study medication. This has now been introduced for 
clonidine as well in the second protocol amendment.
A delay in study start has been encountered in the 
CLOSED study. Several obstacles, such as obtaining 
the appropriate licenses for handling, importing and 
exporting controlled drugs, have caused a significant 
delay in recruitment start. A second major issue has 
also been an amendment of the dose reduction scheme 
(see the ‘Study treatments’ section). A third issue has 
been the generation of robust quality data that is sensi-
tive enough to support a future PUMA application as well 
as the Investigational Medicinal Product Dossier (IMPD) 
and clinical trial application.60
Compliance with the protocol was a significant issue 
in the SLEEPS trial, as they provided a strict sedation 
regimen. Therefore, the CLOSED sedation regimen 
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merely reflects clinical practice, although some important 
aspects may cause difficulties in clinical practice. The 
lock-out periods, for example, are not according to clin-
ical practice and special attention needs to be paid by 
the research nurses and other investigators to keep the 
protocol compliance as tight as possible. When problems 
are recognised, the possibility of amendments should be 
discussed early. Early recognition is facilitated by imple-
mented monthly investigators’ teleconferences.
Also, there will be an ongoing evaluation of the 
COMFORT-B scale training of the nurses in the partici-
pating centres. Good interobserver reliability is defined 
by a Cohen’s kappa >0.65 and nurses in all centres have 
received training by trained nurses.
In summary, many known challenges should be 
managed by appropriate measures taken. However, there 
could always be unknown challenges and it is therefore 
crucial to have regular contact between principal investi-
gators of each recruitment site.
reflection
After 9 months of recruiting, we included far fewer chil-
dren than anticipated. Therefore, two amendments have 
now been added to potentially increase the number of 
eligible patients. Unfortunately, recruitment did not 
improve. Even though we had been warned by the early 
discontinuation of the SLEEPS trial,33 we faced other chal-
lenges. For example, many postoperative neonates do not 
need any additional sedation to intravenous paracetamol 
and continuous intravenous morphine. Also, parents 
are reluctant to participate. Either they think their child 
is not stable enough, or their child is finally stable and 
therefore changes in treatment for study purposes are not 
welcomed.
Also, the anticipated recruitment rate was based on the 
number of admitted ventilated patients in previous years. 
However, this turned out to be a significant overestima-
tion, a phenomenon also known as Lasagna’s Law.61 62 
These challenges have a big impact on the feasibility of 
the trial and force us to consider alternative options. We 
will open (at least) two new recruitment sites, Bari (Italy) 
and Tallinn (Estonia). Furthermore, we need to rethink 
the primary objective of this study and may change it to a 
PK/PD study for which 50 patients in each arm are suffi-
cient instead of the original 150 patients per arm.
The lessons from both the SLEEPS trial and this trial 
are important for further investigations in paediatric crit-
ical care and careful preparation is warranted for any trial 
performed in this population. This preparation should 
at least include adequate piloting over a longer period. 
In our experience, we monitored eligible patients over 
one month in one centre and expected no significant 
recruitment problems. This monitoring was performed 
during winter time, when many patients with respira-
tory viral infections in need of mechanical ventilation 
were admitted. This caused our expectations of eligible 
patients to be high; if we had performed this during 
summer time, we may have been warned earlier.
Other aspects to enhance the number of included 
patients are adequate staff training and motivation, 
collaboration with investigators having experience in 
paediatric critical care trials and keeping the exclusion 
criteria of a trial to a minimum.
trial status
The trial started enrolling subjects in the summer of 2016 
in Rotterdam and Erlangen, where ethical approval is avail-
able. To date, five patients are included. Recruitment in 
other sites will follow when ethical approval becomes avail-
able. The second amendment including changes of the 
exclusion criteria have been submitted to the ethical and 
regulatory institutions and approval has been obtained 
in Rotterdam and Erlangen. The current study protocol, 
including the second amendment, is V.3.0, dated 21 
October 2016. In Rome, Prague and Stockholm, approval 
has only been given for protocol V.2.0, dated 22 February 
2016. Approval for V.3.0 is expected in the first half of 2017.
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